The use of nanoparticles (NPs) has emerged as a potential tool for safe and effective drug delivery. In the present study, we developed small molecule P7C3-based NPs and tested its efficacy and toxicity along with the tissue specific aptamer-modified P7C3 NPs. The P7C3 NPs were prepared using poly (D, L-lactic-co-glycolic acid) carboxylic acid (PLGA-COOH) polymer, were conjugated with skeletal muscle-specific RNA aptamer (A01B P7C3 NPs) and characterized for its cytotoxicity, cellular uptake, and wound healing in vitro. The A01B P7C3 NPs demonstrated an encapsulation efficiency of 30.2 ± 2.6%, with the particle size 255.9 ± 4.3 nm, polydispersity index of 0.335 ± 0.05 and zeta potential of + 10.4 ± 1.8mV. The FTIR spectrum of P7C3 NPs displayed complete encapsulation of the drug in the NPs. The P7C3 NPs and A01B P7C3 NPs displayed sustained drug release in vitro for up to 6 days and qPCR analysis confirmed A01B aptamer binding to P7C3 NPs. The C2C12 cells viability assay displayed no cytotoxic effects of all 3 formulations at 48 and 72 h. In addition, the cellular uptake of A01B P7C3 NPs in C2C12 myoblasts demonstrated higher uptake. In vitro assay mimicking wound healing showed improved wound closure with P7C3 NPs. In addition, P7C3 NPs significantly decreased TNF-α induced NF-κB activity in the C2C12/NF-κB reporter cells after 24-hour treatment. The P7C3 NPs showed 3-4-fold higher efficacy compared to P7C3 solutions in both wound-closure and inflammation assays in C2C12 cells. Furthermore, the P7C3 NPs showed 3-4-fold higher efficacy in reducing the infarct size and protected mouse hearts from ex vivo ischemia-reperfusion injury. Overall, this study demonstrates the safe and effective delivery of P7C3 NPs.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Najahi-Missaoui W, Arnold RD, Cummings BS (2020) Safe nanoparticles: are we there yet? Int J Mol Sci 22. https://doi.org/10.3390/ijms22010385
Wagner S, Manickam R, Brotto M, Tipparaju SM (2022) NAD(+) centric mechanisms and molecular determinants of skeletal muscle disease and aging. Mol Cell Biochem 477:1829–1848. https://doi.org/10.1007/s11010-022-04408-1
Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM, Becker GL, Huntington P, Goldman SE, Shen CH, Capota M, Britt JK, Kotti T, Ure K, Brat DJ, Williams NS, MacMillan KS, Naidoo J, Melito L, Hsieh J, De Brabander J, Ready JM, McKnight SL (2010) Discovery of a proneurogenic, neuroprotective chemical. Cell 142:39–51. https://doi.org/10.1016/j.cell.2010.06.018
Pieper AA, McKnight SL, Ready JM (2014) P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev 43:6716–6726. https://doi.org/10.1039/C3CS60448A
Oku H, Morishita S, Horie T, Kida T, Mimura M, Kojima S, Ikeda T (2017) P7C3 suppresses neuroinflammation and protects retinal ganglion cells of rats from Optic nerve crush. Invest Ophthalmol Vis Sci 58:4877–4888. https://doi.org/10.1167/iovs.17-22179
Rajman L, Chwalek K, Sinclair DA (2018) Therapeutic potential of NAD-Boosting molecules: the in vivo evidence. Cell Metab 27:529–547. https://doi.org/10.1016/j.cmet.2018.02.011
Manickam R, Tur J, Badole SL, Chapalamadugu KC, Sinha P, Wang Z, Russ DW, Brotto M, Tipparaju SM (2022) Nampt activator P7C3 ameliorates diabetes and improves skeletal muscle function modulating cell metabolism and lipid mediators. J Cachexia Sarcopenia Muscle. https://doi.org/10.1002/jcsm.12887
Kilfoil PJ, Chapalamadugu KC, Hu X, Zhang D, Raucci FJ Jr., Tur J, Brittian KR, Jones SP, Bhatnagar A, Tipparaju SM, Nystoriak MA (2019) Metabolic regulation of Kv channels and cardiac repolarization by Kvβ2 subunits. J Mol Cell Cardiol 137:93–106. https://doi.org/10.1016/j.yjmcc.2019.09.013
Tur J, Chapalamadugu KC, Katnik C, Cuevas J, Bhatnagar A, Tipparaju SM (2017) Kvβ1.1 (AKR6A8) senses pyridine nucleotide changes in the mouse heart and modulates cardiac electrical activity. Am J Physiol Heart Circ Physiol 312:H571–h583. https://doi.org/10.1152/ajpheart.00281.2016
Su Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, Wang R, Chen C (2021) PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv 28:1397–1418. https://doi.org/10.1080/10717544.2021.1938756
Athanasiou KA, Niederauer GG, Agrawal CM (1996) Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials 17:93–102. https://doi.org/10.1016/0142-9612(96)85754-1
Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V (2019) An in vitro Assessment of Thermo-Reversible gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech 20:281. https://doi.org/10.1208/s12249-019-1474-0
Ma P, Mumper RJ (2013) Paclitaxel Nano-Delivery Systems: a Comprehensive Review. J Nanomed Nanatechnol 4:1000164–1000164. https://doi.org/10.4172/2157-7439.1000164
Acharya S, Sahoo SK (2011) PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63:170–183. https://doi.org/10.1016/j.addr.2010.10.008
Dvir T, Timko BP, Kohane DS, Langer R (2011) Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol 6:13–22. https://doi.org/10.1038/nnano.2010.246
Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A (2018) Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul 35:204–217. https://doi.org/10.1080/02652048.2018.1453560
Nimjee SM, White RR, Becker RC, Sullenger BA (2017) Aptamers as therapeutics. Annu Rev Pharmacol Toxicol 57:61–79. https://doi.org/10.1146/annurev-pharmtox-010716-104558
Hui Y, Shan L, Lin-Fu Z, Jian-Hua Z (2007) Selection of DNA aptamers against DC-SIGN protein. Mol Cell Biochem 306:71–77. https://doi.org/10.1007/s11010-007-9555-x
Langer R (2001) Drugs on target. Science 293:58–59. https://doi.org/10.1126/science.1063273
Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659. https://doi.org/10.1016/j.addr.2004.02.014
Philippou S, Mastroyiannopoulos NP, Makrides N, Lederer CW, Kleanthous M, Phylactou LA (2018) Selection and identification of skeletal-muscle-targeted RNA aptamers. Mol Therapy - Nucleic Acids 10:199–214. https://doi.org/10.1016/j.omtn.2017.12.004
Narvekar P, Bhatt P, Fnu G, Sutariya V (2019) Axitinib-Loaded poly(Lactic-Co-Glycolic acid) nanoparticles for age-related Macular Degeneration: Formulation Development and in Vitro characterization. Assay Drug Dev Technol 17:167–177. https://doi.org/10.1089/adt.2019.920
Sutariya V, Kelly SJ, Weigel RG, Tur J, Halasz K, Sharma NS, Tipparaju SM (2019) Nanoparticle drug delivery characterization for fluticasone propionate and in vitro testing (1). Can J Physiol Pharmacol 97:675–684. https://doi.org/10.1139/cjpp-2018-0569
Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, Kore G, Misra A (2018) Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J Drug Deliv Sci Technol 45:334–345. https://doi.org/10.1016/J.JDDST.2018.03.027
Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, Mashru R (2018) Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm 536:95–107. https://doi.org/10.1016/j.ijpharm.2017.11.048
Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V (2019) An in vitro Assessment of Thermo-Reversible gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech 20. https://doi.org/10.1208/s12249-019-1474-0
Cooper DL, Harirforoosh S (2014) Design and optimization of PLGA-based diclofenac loaded nanoparticles. PLoS ONE 9:e87326. https://doi.org/10.1371/journal.pone.0087326
Sutariya V, Tur J, Kelly S, Halasz K, Chapalamadugu KC, Nimbalkar R, Pathak YV, Weigel R, Daviau T, Webb T, Cacace J, Brotto M, Tipparaju SM (2018) Nanodrug delivery platform for glucocorticoid use in skeletal muscle injury. Can J Physiol Pharmacol 96:681–689. https://doi.org/10.1139/cjpp-2017-0795
Khanal S, Adhikari U, Rijal NP, Bhattarai SR, Sankar J, Bhattarai N (2016) pH-Responsive PLGA nanoparticle for controlled payload delivery of Diclofenac Sodium. J Funct Biomater 7. https://doi.org/10.3390/jfb7030021
Tur JB, Manickam SL, Chapalamadugu R, Xuan KC, Guida W, Crews W, Bisht JJ, Tipparaju KS SM (2022) Cardioprotective effects of P7C3 in diabetic hearts via Nampt activation. Journal of Pharmacology and Experimental Therapeutics
Sokol MB, Nikolskaya ED, Yabbarov NG, Zenin VA, Faustova MR, Belov AV, Zhunina OA, Mollaev MD, Zabolotsky AI, Tereshchenko OG, Severin ES (2019) Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells. J Biomed Mater Res B Appl Biomater 107:1150–1158. https://doi.org/10.1002/jbm.b.34208
Altındal D, Gümüşderelioğlu M (2016) Melatonin releasing PLGA micro/nanoparticles and their effect on osteosarcoma cells. J Microencapsul 33:53–63. https://doi.org/10.3109/02652048.2015.1115901
Hsu MN, Luo R, Kwek KZ, Por YC, Zhang Y, Chen CH (2015) Sustained release of hydrophobic drugs by the microfluidic assembly of multistage microgel/poly (lactic-co-glycolic acid) nanoparticle composites. Biomicrofluidics 9:052601. https://doi.org/10.1063/1.4916230
Sahana DK, Mittal G, Bhardwaj V, Kumar MN (2008) PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci 97:1530–1542. https://doi.org/10.1002/jps.21158
Wagner S, Manickam R, Brotto M, Tipparaju SM (2022) NAD(+) centric mechanisms and molecular determinants of skeletal muscle disease and aging. Mol Cell Biochem doi. https://doi.org/10.1007/s11010-022-04408-1
Farokhzad OC, Langer R (2009) Impact of Nanotechnology on Drug Delivery. ACS Nano 3:16–20. https://doi.org/10.1021/nn900002m
Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26:442–449. https://doi.org/10.1016/j.tibtech.2008.04.006
Blaya MO, Wasserman JM, Pieper AA, Sick TJ, Bramlett HM, Dietrich WD (2019) Neurotherapeutic capacity of P7C3 agents for the treatment of traumatic brain Injury. Neuropharmacology 145:268–282. https://doi.org/10.1016/j.neuropharm.2018.09.024
Ambasta RK, Sharma A, Kumar P (2011) Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vascular Cell:26%V 3. https://doi.org/10.1186/2045-824x-3-26
Liu L-Y, Wang F, Zhang X-Y, Huang P, Lu Y-B, Wei E-Q, Zhang W-P (2012) Nicotinamide Phosphoribosyltransferase May be involved in age-related Brain Diseases. PLoS ONE 7:e44933. https://doi.org/10.1371/journal.pone.0044933
Wang P, Du H, Zhou C-C, Song J, Liu X, Cao X, Mehta JL, Shi Y, Su D-F, Miao C-Y (2014) Intracellular NAMPT–NAD+–SIRT1 cascade improves post-ischaemic vascular repair by modulating notch signalling in endothelial progenitors. Cardiovascular Res 104:477–488. https://doi.org/10.1093/cvr/cvu220
Baudy AR, Saxena N, Gordish H, Hoffman EP, Nagaraju K (2009) A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int Immunopharmacol 9:1209–1214. https://doi.org/10.1016/j.intimp.2009.07.001
Stout A, Friedly J, Standaert CJ (2019) Systemic absorption and side Effects of locally injected glucocorticoids. Pm r 11:409–419. https://doi.org/10.1002/pmrj.12042
Tipparaju SM, Badole SL, Chapalamadagu KC, Tur J (2020) Methods and uses of nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof. University of South Florida, USA. https://uspto.report/patent/app/20200289466
The authors would also like to acknowledge the Lisa Muma Weitz Laboratory for Advanced Microscopy & Cell Imaging, USF Health, University of South Florida, Tampa, FL, USA for providing facility for microscopy and imaging.
This research was funded by NIH DK119066, and Saunders Endowment to SMT.
The authors declare no competing interests.
US Patent: Patent No.: US 11,007,178 B2 . USF ref. 22A105, 19A039, 24T028. USF Disclosure for aptamer P7C3.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sutariya, V., Bhatt, P., Saini, A. et al. Development and testing of nanoparticles delivery for P7C3 small molecule using injury models. Mol Cell Biochem (2023). https://doi.org/10.1007/s11010-023-04865-2